Published in TB and Outbreaks Week, August 26th, 2003
In liver transplant recipients, the development of IA "is associated with poor response rates and a very high mortality rate, despite administration of therapy with conventional amphotericin B," scientists in the United States explained.
P.K. Linden and colleagues at the University of Pittsburgh "conducted a single-center, retrospective study to compare the outcome of liver transplant recipients with IA who received amphotericin B lipid complex (ABLC) or conventional amphotericin B."
"IA was present in 12...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.